Phase 4
N=500
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT05579249 ↗Enrolled (actual)
500
Serious AEs
2.3%
Results posted
Jan 2026
Primary outcome: Primary: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) — 132; 61; 75; 116 Participants — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Semaglutide (Drug); Orlistat (Drug); Phentermine/Topiramate (Drug); Naltrexone/Bupropion (Drug); Liraglutide (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Novo Nordisk A/S
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) |
132; 61; 75; 116 | <0.0001 sig |
| SECONDARY Percentage Change in Body Weight |
-13.6; -7.4 | — |
| SECONDARY Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain |
25.6; 22.6 | — |
| SECONDARY Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no) |
93; 25; 114; 152 | — |
| SECONDARY Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no) |
49; 8; 158; 169 | — |
| SECONDARY Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no) |
138; 108; 51; 55 | — |
| SECONDARY Percentage of Days Covered (PDC) by Study Product |
83.7; 70.8 | — |
| SECONDARY Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no) |
168; 113; 82; 137 | — |
| SECONDARY Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS) |
-0.034; -0.016 | — |
Summary
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).
Eligibility Criteria
Inclusion Criteria
- Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m^2).
- Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.
Exclusion Criteria
- Known or suspected hypersensitivity or contraindications to Wegovy or related products according to the label.
- Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
- History of type 1 or type 2 diabetes mellitus.
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.
Data sourced from ClinicalTrials.gov (NCT05579249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.